Eli Lilly Retained Earnings (Accumulated Deficit) 2010-2024 | LLY

Eli Lilly retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $13.627B, a 32.18% increase year-over-year.

  • Eli Lilly retained earnings (accumulated deficit) for 2023 were $10.312B, a 2.69% increase from 2022.
  • Eli Lilly retained earnings (accumulated deficit) for 2022 were $10.043B, a 12.1% increase from 2021.
  • Eli Lilly retained earnings (accumulated deficit) for 2021 were $8.959B, a 14.41% increase from 2020.

Eli Lilly Retained Earnings (Accumulated Deficit) 2010-2024 | LLY

  • Eli Lilly retained earnings (accumulated deficit) for 2023 were $10.312B, a 2.69% increase from 2022.
  • Eli Lilly retained earnings (accumulated deficit) for 2022 were $10.043B, a 12.1% increase from 2021.
  • Eli Lilly retained earnings (accumulated deficit) for 2021 were $8.959B, a 14.41% increase from 2020.
Related Stocks
Company NameMarket
Cap
Novo Nordisk (NVO)$460.6B
Johnson & Johnson (JNJ)$368.4B
AbbVie (ABBV)$294.4B
Merck (MRK)$244.2B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B